NDA 22266, held by Adalvo. Fentanyl Citrate.
As of Nov 13, 2026, NDA 22266 (Onsolis), held by Adalvo, was first approved by FDA on Jul 16, 2009, with 14 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2009 | Original applicationNew dosage form · Standard review | Approved |
| OnsolisEQ 0.2MG BASE · film;buccal | Fentanyl Citrate | Discontinued |
| OnsolisEQ 0.4MG BASE · film;buccal | Fentanyl Citrate | Discontinued |
| OnsolisEQ 0.6MG BASE · film;buccal | Fentanyl Citrate | Discontinued |
| OnsolisEQ 0.8MG BASE · film;buccal | Fentanyl Citrate | Discontinued |
| OnsolisEQ 1.2MG BASE · film;buccal | Fentanyl Citrate | Discontinued |
| Aug 17, 2022 | Supplement 27REMS | Approved | |
| Dec 3, 2021 | Supplement 26REMS | Approved | |
| Mar 4, 2021 | Supplement 25Labeling · Standard review | Approved | |
| Dec 23, 2020 | Supplement 24REMS | Approved | |
| Oct 7, 2019 | Supplement 23Labeling · Standard review | Approved | |
| Sep 7, 2017 | Supplement 19REMS | Approved | |
| Dec 16, 2016 | Supplement 17Labeling · Standard review | Approved | |
| Dec 16, 2016 | Supplement 18Labeling · Standard review | Approved | |
| Aug 11, 2015 | Supplement 15Manufacturing · Standard review | Approved | |
| Dec 24, 2014 | Supplement 14REMS | Approved | |
| Nov 7, 2013 | Supplement 12REMS | Approved | |
| Jun 5, 2012 | Supplement 9REMS | Approved | |
| Dec 28, 2011 | Supplement 8REMS | Approved | |
| Jul 1, 2010 | Supplement 1REMS | Approved | |
| Jul 16, 2009 | Original applicationNew dosage form · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters